These data suggest that increased STAT3 signaling is critical for Olaparib resistance in BRCA wild-type and BRCA2-mutated ovarian cancer cells by promoting the expression of genes essential for proliferation and anti-apoptosis. This evidence concerns the gene BRCA2 and ovarian carcinoma.